BiotechTube

Remestemcel-L

Phase 3Completed
1 views this week 0 watching💤 Quiet
Interest: 34/100
34
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Grade B Acute Graft Versus Host Disease

Conditions

Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease

Trial Timeline

Oct 28, 2015 → Jun 15, 2018

NCT ID
NCT02652130

About Remestemcel-L

Remestemcel-L is a phase 3 stage product being developed by Mesoblast for Grade B Acute Graft Versus Host Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT02652130. Target conditions include Grade B Acute Graft Versus Host Disease, Grade C Acute Graft Versus Host Disease, Grade D Acute Graft Versus Host Disease.

What happened to similar drugs?

0 of 6 similar drugs in Grade B Acute Graft Versus Host Disease were approved

Approved (0) Terminated (1) Active (5)
🔄diclofenac diethylamine gel 2.32% + diclofenac diethylamine gel 2.32% + PlaceboNovartisPhase 3
❌MEK162, MEK inhibitor; oral + Physician's choice chemotherapyPfizerPhase 3
🔄rituximabBiogenPhase 3
🔄Tovorafenib + Chemotherapeutic AgentDay One BiopharmaceuticalsPhase 3
🔄remestemcel-LMesoblastPhase 3
🔄avutometinib + Defactinib + Pegylated liposomal doxorubicin + Paclitaxel + Letrozole + AnastrozoleVerastem OncologyPhase 3

Hype Score Breakdown

Clinical
17
Activity
8
Company
9
Novelty
0
Community
0

Clinical Trials (4)

NCT IDPhaseStatus
NCT04366830Pre-clinicalCompleted
NCT00759018Pre-clinicalCompleted
NCT02652130Phase 3Completed
NCT02336230Phase 3Completed

Competing Products

20 competing products in Grade B Acute Graft Versus Host Disease

See all competitors
ProductCompanyStageHype Score
[203Pb]VMT-α-NETPerspective TherapeuticsPhase 1
27
azenosertibZentalis PharmaceuticalsPhase 2
32
Sepantronium BromideCothera BiosciencePhase 2
29
DS-1001bDaiichi SankyoPhase 2
39
Rabeprazole SodiumEisaiPre-clinical
26
Binimetinib 15 MGOno PharmaceuticalPhase 2
42
Abemaciclib + LetrozoleEli LillyPhase 2
42
Pirtobrutinib + MosunetuzumabEli LillyPhase 2
42
Pembrolizumab + Pemetrexed + AbemaciclibEli LillyPhase 1
21
DSP-0390Sumitomo PharmaPhase 1
33
Mirvetuximab soravtansine + CarboplatinAbbViePhase 2
39
Mirvetuximab SoravtansineAbbViePhase 2
42
Acalabrutinib + ObinutuzumabAstraZenecaPhase 2
42
Olaparib Pill + AZD6738AstraZenecaPhase 2
35
PembrolizumabMerckPhase 2
42
Efineptakin alfa + PembrolizumabMerckPhase 2
42
PembrolizumabMerckPhase 2
39
Pembrolizumab + Paclitaxel + Carboplatin + Avastin + MK-4830 + DocetaxelMerckPhase 2
35
CilengitideMerckPhase 2
31
AvelumabMerckPhase 2
35